Literature DB >> 15619028

Gas6, warfarin, and kidney diseases.

Motoko Yanagita1.   

Abstract

The product of growth arrest-specific gene 6 (Gas6) is a unique vitamin K-dependent autocrine growth factor for mesangial cells, and warfarin inhibits mesangial cell proliferation by interfering with the activation process of Gas6. A recent series of studies has revealed the in vivo roles of Gas6 and its receptor Axl in the progression of acute and chronic glomerulonephritis, diabetic nephropathy, chronic allograft rejection, and human kidney diseases. This review summarizes these studies and discusses the possible interventions targeting the Gas6/Axl pathway to prevent the progression of kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619028     DOI: 10.1007/s10157-004-0305-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  20 in total

1.  Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis.

Authors:  Chien-Sheng Wu; Chung-Yi Hu; Hwei-Fang Tsai; I-Tsu Chyuan; Cheng-Ju Chan; Sheng-Kai Chang; Ping-Ning Hsu
Journal:  Rheumatol Int       Date:  2013-11-01       Impact factor: 2.631

2.  Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.

Authors:  Kyle Ware; Polina Brodsky; Anjali A Satoskar; Tibor Nadasdy; Gyongyi Nadasdy; Haifeng Wu; Brad H Rovin; Udayan Bhatt; Jon Von Visger; Lee A Hebert; Sergey V Brodsky
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

Review 3.  Pathogenesis of glomerular haematuria.

Authors:  Claudia Yuste; Eduardo Gutierrez; Angel Manuel Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Alberto Ortiz; Jesus Egido; Manuel Praga; Juan Antonio Moreno
Journal:  World J Nephrol       Date:  2015-05-06

4.  Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate.

Authors:  Sergey V Brodsky; Tibor Nadasdy; Brad H Rovin; Anjali A Satoskar; Gyongyi M Nadasdy; Haifeng M Wu; Udayan Y Bhatt; Lee A Hebert
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

Review 5.  Oral anticoagulants and risk of nephropathy.

Authors:  Vinay Narasimha Krishna; David G Warnock; Nakshatra Saxena; Dana V Rizk
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

6.  Opposing Roles of Tyrosine Kinase Receptors Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated Nephritis.

Authors:  Yuxuan Zhen; Stephen O Priest; Wen-Hai Shao
Journal:  J Immunol       Date:  2016-08-15       Impact factor: 5.422

7.  Reduction of Stat3 activity attenuates HIV-induced kidney injury.

Authors:  Xiaobei Feng; Ting-Chi Lu; Peter Y Chuang; Wei Fang; Krishna Ratnam; Huabao Xiong; Xinshou Ouyang; Yuhong Shen; David E Levy; Deborah Hyink; Mary Klotman; Vivette D'Agati; Ravi Iyengar; Paul E Klotman; John C He
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

8.  Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure.

Authors:  Iris J Lee; Brendan Hilliard; Abhishek Swami; John C Madara; Swati Rao; Tapan Patel; John P Gaughan; Jean Lee; Crystal A Gadegbeku; Eric T Choi; Philip L Cohen
Journal:  Nephrol Dial Transplant       Date:  2012-08-20       Impact factor: 5.992

9.  Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease.

Authors:  Tamer A Gheita; Iman H Bassyouni; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-07-26       Impact factor: 8.317

Review 10.  Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2009-04-11       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.